DDInter195 DDInter1676
Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Betamethasone {u} (Compound) resembles {v} (Compound) Mometasone
Betamethasone {u} (Compound) resembles {v} (Compound) Fludrocortisone
Betamethasone {u} (Compound) treats {v} (Disease) allergic rhinitis
Betamethasone {u} (Compound) binds {v} (Gene) CYP3A4
Betamethasone {u} (Compound) upregulates {v} (Gene) GSPT1
Betamethasone {u} (Compound) palliates {v} (Disease) kidney cancer
Betamethasone {u} (Compound) is included by {v} (Pharmacologic Class) Corticosteroid Hormone Receptor Agonists
Betamethasone {u} (Compound) downregulates {v} (Gene) DDIT3
Betamethasone {u} (Compound) causes {v} (Side Effect) Blindness
Betamethasone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Orciprenaline
Betamethasone (Compound) resembles Mometasone (Compound)
Betamethasone (Compound) resembles Fludrocortisone (Compound)
Betamethasone (Compound) treats allergic rhinitis (Disease)
Betamethasone (Compound) binds CYP3A4 (Gene)
Betamethasone (Compound) upregulates GSPT1 (Gene)
Betamethasone (Compound) palliates kidney cancer (Disease)
Betamethasone (Compound) is included by Corticosteroid Hormone Receptor Agonists (Pharmacologic Class)
Betamethasone (Compound) downregulates DDIT3 (Gene)
Betamethasone (Compound) causes Blindness (Side Effect)
Betamethasone may cause a minor interaction that can limit clinical effects when taken with Orciprenaline